|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-1-19
|
|
pubmed:abstractText |
To assess the efficacy of 24- or 48-week peginterferon/ribavirin treatment of Taiwanese patients with chronic hepatitis C virus genotype-1b (HCV-1b) infection, and to identify subgroups of patients in whom the 48-week treatment has benefits.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1478-3223
|
|
pubmed:author |
pubmed-author:ChangWen-YuWY,
pubmed-author:ChenShinn-CherngSC,
pubmed-author:ChuangWan-LongWL,
pubmed-author:DaiChia-YenCY,
pubmed-author:HouNei-JenNJ,
pubmed-author:HsiehMing-YenMY,
pubmed-author:HsiehMing-YuhMY,
pubmed-author:LeeLi-PoLP,
pubmed-author:LinZu-YauZY,
pubmed-author:WangLiang-YenLY,
pubmed-author:YuMing-LungML
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
73-81
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16420512-Adult,
pubmed-meshheading:16420512-Antiviral Agents,
pubmed-meshheading:16420512-Dose-Response Relationship, Drug,
pubmed-meshheading:16420512-Drug Administration Schedule,
pubmed-meshheading:16420512-Drug Therapy, Combination,
pubmed-meshheading:16420512-Female,
pubmed-meshheading:16420512-Follow-Up Studies,
pubmed-meshheading:16420512-Genotype,
pubmed-meshheading:16420512-Hepacivirus,
pubmed-meshheading:16420512-Hepatitis C, Chronic,
pubmed-meshheading:16420512-Humans,
pubmed-meshheading:16420512-Interferon-alpha,
pubmed-meshheading:16420512-Liver Function Tests,
pubmed-meshheading:16420512-Male,
pubmed-meshheading:16420512-Maximum Tolerated Dose,
pubmed-meshheading:16420512-Middle Aged,
pubmed-meshheading:16420512-Pilot Projects,
pubmed-meshheading:16420512-Polyethylene Glycols,
pubmed-meshheading:16420512-Probability,
pubmed-meshheading:16420512-ROC Curve,
pubmed-meshheading:16420512-Recombinant Proteins,
pubmed-meshheading:16420512-Reference Values,
pubmed-meshheading:16420512-Ribavirin,
pubmed-meshheading:16420512-Risk Assessment,
pubmed-meshheading:16420512-Severity of Illness Index,
pubmed-meshheading:16420512-Single-Blind Method,
pubmed-meshheading:16420512-Taiwan,
pubmed-meshheading:16420512-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
|
|
pubmed:affiliation |
Hepatobiliary Division, Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
